ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours-Reference-Cited by-同舟云学术

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours

Published:2016-05-31 Issue:1 Volume:16 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Segelov Eva,Waring Paul,Desai Jayesh,Wilson Kate,Gebski Val,Thavaneswaran Subotheni,Elez Elena,Underhill Craig,Pavlakis Nick,Chantrill Lorraine,Nott Louise,Jefford Michael,Khasraw Mustafa,Day Fiona,Wasan Harpreet,Ciardiello Fortunato,Karapetis Chris,Joubert Warren,van Hazel Guy,Haydon Andrew,Price Tim,Tejpar Sabine,Tebbutt Niall,Shapiro Jeremy

Funder

Merck Serono Australia Pty Ltd.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-016-2389-8

Reference20 articles.

1. Cunningham D et al. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer. New Engl J Med. 2004;351:337–45.

2. Van Cutsem E et al. Open-label phase III trial of panitumumab plus best supportiive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658–64.

3. Siu L et al. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial. J Clin Oncol. 2013;31:2477–84.